Main Menu
Menu

Show posts

This section allows you to view all posts made by this member. Note that you can only see posts made in areas you currently have access to.

Show posts Menu

Topics - Flux

#21
Riga MS, Soria G, Tudela R, Artigas F & Celada, P 2014, 'The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs', International Journal of Neuropsychopharmacoly, vol. 17, no. 8, pp. 1269-1282. DOI: https://doi.org/10.1017/S1461145714000261

Abstract

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a natural hallucinogen component of Ayahuasca, an Amazonian beverage traditionally used for ritual, religious and healing purposes that is being increasingly used for recreational purposes in US and Europe. 5MeO-DMT is of potential interest for schizophrenia research owing to its hallucinogenic properties. Two other psychotomimetic agents, phencyclidine and 2,5-dimethoxy-4-iodo-phenylisopropylamine (DOI), markedly disrupt neuronal activity and reduce the power of low frequency cortical oscillations (<4 Hz, LFCO) in rodent medial prefrontal cortex (mPFC). Here we examined the effect of 5-MeO-DMT on cortical function and its potential reversal by antipsychotic drugs. Moreover, regional brain activity was assessed by blood-oxygen level dependent (BOLD) functional magnetic resonance imaging (fMRI). 5-MeO-DMT disrupted mPFC activity, increasing and decreasing the discharge of 51 and 35% of the recorded pyramidal neurons, and reducing (−31%) the power of LFCO. The latter effect depended on 5-HT1A and 5-HT2A receptor activation and was reversed by haloperidol, clozapine, risperidone, and the mGlu2/3 agonist LY379268. Likewise, 5-MeO-DMT decreased BOLD responses in visual cortex (V1) and mPFC. The disruption of cortical activity induced by 5-MeO-DMT resembles that produced by phencyclidine and DOI. This, together with the reversal by antipsychotic drugs, suggests that the observed cortical alterations are related to the psychotomimetic action of 5-MeO-DMT. Overall, the present model may help to understand the neurobiological basis of hallucinations and to identify new targets in antipsychotic drug development.
#22
Thomson KK, Ruiz EM, Masten V, Buell M & Geyer MA, 2006, 'The Roles of 5-HT1A and 5-HT2 Receptors in the Effects of 5-MeO-DMT on Locomotor Activity and Prepulse Inhibition in Rats', Psychopharmacology, vol. 189, no. 3, pp. 319–329, https://link.springer.com/article/10.1007/s00213-006-0566-1

RATIONALE
The hallucinogen 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is structurally similar to other indoleamine hallucinogens such as LSD. The present study examined the effects of 5-MeO-DMT in rats using the Behavioral Pattern Monitor (BPM), which enables analyses of patterns of locomotor activity and exploration, and the prepulse inhibition of startle (PPI) paradigm.
OBJECTIVES
A series of interaction studies using the serotonin (5-HT)1A antagonist WAY-100635 (1.0 mg/kg), the 5-HT2A antagonist M100907 (1.0 mg/kg), and the 5-HT2C antagonist SER-082 (0.5 mg/kg) were performed to assess the respective contributions of these receptors to the behavioral effects of 5-MeO-DMT (0.01, 0.1, and 1.0 mg/kg) in the BPM and PPI paradigms.
RESULTS
5-MeO-DMT decreased locomotor activity, investigatory behavior, the time spent in the center of the BPM chamber, and disrupted PPI. All of these effects were antagonized by WAY-100635 pretreatment. M100907 pretreatment failed to attenuate any of these effects, while SER-082 pretreatment only antagonized the PPI disruption produced by 5-MeO-DMT.
CONCLUSIONS
While the prevailing view was that the activation of 5-HT2 receptors is solely responsible for hallucinogenic drug effects, these results support a role for 5-HT1A receptors in the effects of the indoleamine hallucinogen 5-MeO-DMT on locomotor activity and PPI in rats.
#23
Halberstadt AL, Buell MR, Masten VL, Risbrough VB & Geyer MA, 2008, 'Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors', Psychopharmacology, vol. 201, no. 1, pp. 55-66, doi: 10.1007/s00213-008-1247-z, https://www.ncbi.nlm.nih.gov/pubmed/18604652

Abstract

RATIONALE:
The hallucinogenic tea known as ayahuasca is made from a combination of psychoactive plants that contribute the active components N,N-dimethyltryptamine (DMT) and 5-methoxy-DMT (5-MeO-DMT), as well as the monoamine oxidase (MAO) inhibitors (MAOIs) harmine and harmaline for oral activity.
OBJECTIVE:
The present study examined the effects of 5-MeO-DMT in combination with MAOIs in rats using the behavioral pattern monitor, which enables analyses of patterns of locomotor activity and exploration. Interaction studies using the serotonin (5-HT)(1A) antagonist WAY-100635 (1.0 mg/kg) and the 5-HT(2A) antagonist MDL 11,939 (1.0 mg/kg) were also performed to assess the respective contributions of these receptors to the behavioral effects of 5-MeO-DMT in MAOI-treated animals.
RESULTS:
5-MeO-DMT (0.01, 0.1, and 1.0 mg/kg) decreased locomotor activity and investigatory behavior. In rats pretreated with a behaviorally inactive dose of harmaline (0.1 mg/kg), 1.0 mg/kg 5-MeO-DMT had biphasic effects on locomotor activity, initially reducing locomotion and then increasing activity as time progressed. The ability of harmaline to shift 5-MeO-DMT to a biphasic locomotor pattern was shared by the selective MAO(A) inhibitor clorgyline, whereas the selective MAO(B) inhibitor (-)-deprenyl was ineffective. The late hyperactivity induced by the combination of 1.0 mg/kg 5-MeO-DMT and 0.3 mg/kg clorgyline was blocked by pretreatment with MDL 11,939. Pretreatment with WAY-100635 failed to attenuate either the early hypoactivity or the late hyperactivity.
CONCLUSIONS:
The ability of harmaline to modify the behavioral effects of 5-MeO-DMT is mediated by the inhibition of MAO(A). Furthermore, 5-HT(2A) receptors are responsible for the late hyperactivity induced by 5-MeO-DMT in the presence of MAO(A) inhibitors.
#24
Jiang XL, Shen HW & Yu AM, 2016, 'Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms', Pharmacological Reports, vol. 68, no. 3, pp. 608-15, doi: 10.1016/j.pharep.2016.01.008, https://www.ncbi.nlm.nih.gov/pubmed/26977821

Abstract

BACKGROUND:
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and harmaline are indolealkylamine (IAA) drugs often abused together. Our recent studies have revealed the significant effects of co-administered harmaline, a monoamine oxidase inhibitor (MAOI), on 5-MeO-DMT pharmacokinetics and thermoregulation. This study was to delineate the impact of harmaline and 5-MeO-DMT on home-cage activity in mouse models, as well as the contribution of serotonin (5-HT) receptors.
METHODS:
Home-cage activities of individual animals were monitored automatically in the home cages following implantation of telemetry transmitters and administration of various doses of IAA drugs and 5-HT receptor antagonists. Area under the effect curve (AUEC) of mouse activity values were calculated by trapezoidal rule.
RESULTS:
High dose of harmaline (15mg/kg, ip) alone caused an early-phase (0-45min) hypoactivity in mice that was fully attenuated by 5-HT1A receptor antagonist WAY-100635, whereas a late-phase (45-180min) hyperactivity that was reduced by 5-HT2A receptor antagonist MDL-100907. 5-MeO-DMT (10 and 20mg/kg, ip) alone induced biphasic effects, an early-phase (0-45min) hypoactivity that was completely attenuated by WAY-100635, and a late-phase (45-180min) hyperactivity that was fully suppressed by MDL-100907. Interestingly, co-administration of MAOI harmaline (2-15mg/kg) with a subthreshold dose of 5-MeO-DMT (2mg/kg) induced excessive hyperactivities at late phase (45-180min) that could be abolished by either WAY-100635 or MDL-100907.
CONCLUSIONS:
Co-administration of MAOI with 5-MeO-DMT provokes excessive late-phase hyperactivity, which involves the activation of both 5-HT1A and 5-HT2A receptors
#25
Winter JC, Amorosi DJ, Rice KC, Cheng K & Yu AM, 2011, 'Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized mice', Pharmacology Biochemistry and Behavior, vol. 99, no. 3, pp. 311-5, doi: 10.1016/j.pbb.2011.05.015, https://www.ncbi.nlm.nih.gov/pubmed/21624387

Abstract

In previous studies we have observed that, in comparison with wild type mice, Tg-CYP2D6 mice have increased serum levels of bufotenine [5-hydroxy-N,N-dimethyltryptamine] following the administration of 5-MeO-DMT. Furthermore, following the injection of 5-MeO-DMT, harmaline was observed to increase serum levels of bufotenine and 5-MeO-DMT in both wild-type and Tg-CYP2D6 mice. In the present investigation, 5-MeO-DMT-induced stimulus control was established in wild-type and Tg-CYP2D6 mice. The two groups did not differ in their rate of acquisition of stimulus control. When tested with bufotenine, no 5-MeO-DMT-appropriate responding was observed. In contrast, the more lipid soluble analog of bufotenine, acetylbufotenine, was followed by an intermediate level of responding. The combination of harmaline with 5-MeO-DMT yielded a statistically significant increase in 5-MeO-DMT-appropriate responding in Tg-CYP2D6 mice; a comparable increase occurred in wild-type mice. In addition, it was noted that harmaline alone was followed by a significant degree of 5-MeO-DMT-appropriate responding in Tg-CYP2D6 mice. It is concluded that wild-type and Tg-CYPD2D6 mice do not differ in terms of acquisition of stimulus control by 5-MeO-DMT or in their response to bufotenine and acetylbufotenine. In both groups of mice, harmaline was found to enhance the stimulus effects of 5-MeO-DMT.
#26
Jiang XL, Shen HW, Yu AM, 2015, 'Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors’, Neuropharmacology,  vol. 89, pp. 342-51, https://www.ncbi.nlm.nih.gov/pubmed/25446678

Abstract

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and harmaline are serotonin (5-HT) analogs often abused together, which alters thermoregulation that may indicate the severity of serotonin toxicity. Our recent studies have revealed that co-administration of monoamine oxidase inhibitor harmaline leads to greater and prolonged exposure to 5-HT agonist 5-MeO-DMT that might be influenced by cytochrome P450 2D6 (CYP2D6) status. This study was to define the effects of harmaline and 5-MeO-DMT on thermoregulation in wild-type and CYP2D6-humanized (Tg-CYP2D6) mice, as well as the involvement of 5-HT receptors. Animal core body temperatures were monitored noninvasively in the home cages after implantation of telemetry transmitters and administration of drugs. Harmaline (5 and 15 mg/kg, i.p.) alone was shown to induce hypothermia that was significantly affected by CYP2D6 status. In contrast, higher doses of 5-MeO-DMT (10 and 20 mg/kg) alone caused hyperthermia. Co-administration of harmaline (2, 5 or 15 mg/kg) remarkably potentiated the hyperthermia elicited by 5-MeO-DMT (2 or 10 mg/kg), which might be influenced by CYP2D6 status at certain dose combination. Interestingly, harmaline-induced hypothermia was only attenuated by 5-HT1A receptor antagonist WAY-100635, whereas 5-MeO-DMT- and harmaline-5-MeO-DMT-induced hyperthermia could be suppressed by either WAY-100635 or 5-HT2A receptor antagonists (MDL-100907 and ketanserin). Moreover, stress-induced hyperthermia under home cage conditions was not affected by WAY-100635 but surprisingly attenuated by MDL-100907 and ketanserin. Our results indicate that co-administration of monoamine oxidase inhibitor largely potentiates 5-MeO-DMT-induced hyperthermia that involves the activation of both 5-HT1A and 5-HT2A receptors. These findings shall provide insights into development of anxiolytic drugs and new strategies to relieve the lethal hyperthermia in serotonin toxicity.
#27
Callaway JC, Grob CS, McKenna DJ, Nichols DE, Shulgin A & Tupper KW,  2006, 'A Demand for Clarity Regarding a Case Report on the Ingestion of S-Methoxy-N, N-Dimethyltryptamine (5-MeO·DMT) in an Ayahuasca Preparation'€, Journal of Analytical Toxicology, vol.30, https://www.ncbi.nlm.nih.gov/pubmed/16872575

First Sentence of Letter to Editor;

"The case report 'A Fatal Intoxication Following theIngestion of5-Methoxy-N,N-Dimethyltryptamine in an Ayahuasca Preparation' by Sklerov et al. is misleading as to the nature and toxicity of ayahuasca". 
#28
Sklerov J, Levine B, Moore KA, King T & Fowler A, 2005, 'A Fatal Intoxication Following the Ingestion of 5-Methoxy-N,N-Dimethyltryptamine in an Ayahuasca Preparation', Journal of Analytical Toxicology, vol. 29, no.8, pp. 38-41, DOI: 10.1093/jat/29.8.838, https://www.researchgate.net/publication/7414522_A_Fatal_Intoxication_Following_the_Ingestion_of_5-Methoxy-NN-Dimethyltryptamine_in_an_Ayahuasca_Preparation

Abstract

A case of a 25-year-old white male who was found dead the morning after consuming herbal extracts containing β-carbolines and hallucinogenic tryptamines is presented. No anatomic cause of death was found at autopsy. Toxicologic analysis of the heart blood identified N,N-dimethyltryptamine (0.02 mg/L), 5-methoxy-N,N-dimethyltryptamine (1.88 mg/L), tetrahydroharmine (0.38 mg/L), harmaline (0.07 mg/L), and harmine (0.17 mg/L). All substances were extracted by a single-step n-butyl chloride extraction following alkalinization with borate buffer. Detection and quantitation was performed using liquid chromatography-electrospray mass spectrometry. The medical examiner ruled that the cause of death was hallucinogenic amine intoxication, and the manner of death was undetermined.
#29
Ott J, 2011, 'Pharmepena-Psychonautics: Human Intranasal, Sublingual and Oral Pharmacology of 5-Methoxy-N, N-Dimethyl-Tryptamine', Journal
Journal of Psychoactive Drugs
, vol. 33, 2001, no. 4, http://www.tandfonline.com/doi/abs/10.1080/02791072.2001.10399925

Abstract

Summarized are psychonautic bioassays (human self-experiments) of Pharmepena - crystalline 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT; O-Me-bufotenine), at times combined with crystalline b-Carboline (harmaline or harmine). These substances were administered via intranasal, sublingual and oral routes, by way of pharmacological modeling of diverse South American shamanic inebriants (principally the snuffs epena/nyakwana, prepared from barks of diverse species of Virola.) Intranasal, sublingual and oral psychoactivity of 5-MeO-DMT, and the 1967 Holmstedt-Lindgren hypothesis of the parica-effect - intranasal potentiation of tryptamines by concomitant administration of monoamine-oxidase-inhibiting (MAOI) b-Carboline from stems of Banisteriopsis caapi admixed with the snuffs - have been confirmed by some 17 psychonautic bioassays. Salient phytochemical and psychonautic literature is reviewed.
#30
Jiang XL, Shen HW, Mager DE & Yu AM, 2013, 'Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status', Drug Metabolism and Disposition, vol. 41, no. 5, pp. 975-986, DOI: doi.org/10.1124/dmd.112.050724, http://dmd.aspetjournals.org/content/41/5/975

Abstract

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT or street name "5-MEO") is a newer designer drug belonging to a group of naturally occurring indolealkylamines. Our recent study has demonstrated that coadministration of monoamine oxidase A (MAO-A) inhibitor harmaline (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine. This study is aimed at delineating harmaline and 5-MeO-DMT pharmacokinetic (PK) interactions at multiple dose levels, as well as the impact of CYP2D6 that affects harmaline PK and determines 5-MeO-DMT O-demethylation to produce bufotenine. Our data revealed that inhibition of MAO-A-mediated metabolic elimination by harmaline (2, 5, and 15 mg/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg/kg) at all dose combinations. A more pronounced effect on 5-MeO-DMT PK was associated with greater exposure to harmaline in wild-type mice than CYP2D6-humanized (Tg-CYP2D6) mice. Harmaline (5 mg/kg) also increased blood and brain bufotenine concentrations that were generally higher in Tg-CYP2D6 mice. Surprisingly, greater harmaline dose (15 mg/kg) reduced bufotenine levels. The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6. Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models. This PK model may be further employed to predict harmaline and 5-MeO-DMT PK interactions at various doses, define the impact of CYP2D6 status, and drive harmaline-5-MeO-DMT pharmacodynamics.
#31
Hong-Wu S,  Xi-Ling J, Winter JC & Yu AM, 2010, 'Psychedelic 5-Methoxy-N,N-Dimethyltryptamine: Metabolism, Pharmacokinetics, Drug Interactions, and Pharmacological Actions', Current Drug Metabolism, vol. 11, no. 8, pp. 659-666, doi 10.2174/138920010794233495, https://www.ncbi.nlm.nih.gov/pubmed/20942780

Abstract

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) belongs to a group of naturally-occurring psychoactive indolealkylamine drugs. It acts as a nonselective serotonin (5-HT) agonist and causes many physiological and behavioral changes. 5-MeO-DMT is O-demethylated by polymorphic cytochrome P450 2D6 (CYP2D6) to an active metabolite, bufotenine, while it is mainly inactivated through the deamination pathway mediated by monoamine oxidase A (MAO-A). 5-MeO-DMT is often used with MAO-A inhibitors such as harmaline. Concurrent use of harmaline reduces 5-MeO-DMT deamination metabolism and leads to a prolonged and increased exposure to the parent drug 5-MeO-DMT, as well as the active metabolite bufotenine. Harmaline, 5-MeO-DMT and bufotenine act agonistically on serotonergic systems and may result in hyperserotonergic effects or serotonin toxicity. Interestingly, CYP2D6 also has important contribution to harmaline metabolism, and CYP2D6 genetic polymorphism may cause considerable variability in the metabolism, pharmacokinetics and dynamics of harmaline and its interaction with 5-MeO-DMT. Therefore, this review summarizes recent findings on biotransformation, pharmacokinetics, and pharmacological actions of 5-MeO-DMT. In addition, the pharmacokinetic and pharmacodynamic drug-drug interactions between harmaline and 5-MeO-DMT, potential involvement of CYP2D6 pharmacogenetics, and risks of 5-MeO-DMT intoxication are discussed.
#32
Media/Resources / 5-MeO-DMT User's Guide
May 01, 2017, 03:01:30 AM
The following is a document published by Martin Ball as "a clear and easy to understand guide in question and answer format concerning the use of 5-MeO-DMT as an entheogenic tool for expansion of human awareness" 5-MeO-DMT Users Guide
#33

Wade D & Weil A, 1994, ‘Bufo alvarius: A Potent Hallucinogen of Animal Origin’, Journal of Ethnopharmacology, vol. 41, nos. 1-2, pp. 1-8, https://www.ncbi.nlm.nih.gov/pubmed/8170151

Abstract:

Anthropologists have long speculated that ancient peoples of Mesoamerica used a toad, Bufo marinus, as a ritual intoxicant. This hypothesis rests on many iconographic and mythological representations of toads and on a number of speculative ethnographic reports. The authors reject B. marinus as a candidate for such use because of the toxicity of its venom. A more likely candidate is the Sonoran desert toad, Bufo alvarius, which secretes large amounts of the potent known hallucinogen, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). The authors demonstrate that the venom of B. alvarius, although known to be toxic when consumed orally, may be safely smoked and is powerfully psychoactive by that route of administration. These experiments are the first documentation of an hallucinogenic agent from the animal kingdom, and they provide clear evidence of a psychoactive toad that could have been employed by Precolumbian peoples of the New World
#34
Davis W & Weil A, 1992, ‘Identity of a New World Psychoactive Toad’, Ancient Mesoamerica, vol. 3, no. 1, pp. 51-59. DOI: 10.1017/S0956536100002297, https://www.researchgate.net/publication/232002148_Identity_of_a_New_World_Psychoactive_Toad

Abstract

Anthropologists have long speculated that ancient peoples of Mesoamerica used a toad, Bufo marinus, as a ritual intoxicant. This hypothesis rests on many iconographic and mythological representations of toads and on a number of speculative ethnographic reports. We reject B. marinus as a candidate for such use because of the toxicity of its venom. A more likely candidate is the Sonoran desert toad, Bufo alvarius, which secretes large amounts of the potent, known hallucinogen, 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT). We demonstrate that the venom of B. alvarius, though known to be toxic when consumed orally, may be safely smoked and is powerfully psychoactive by that route of administration. These experiments are the first documentation of a hallucinogenic agent from the animal kingdom, and they provide clear evidence of a psychoactive toad that could have been employed by Precolumbiae peoples of the New World.
#35
Lyttle T, Goldstein, D & Gartz J,'Bufo Toads and Bufotenine: Fact and Fiction Surrounding an Alleged Psychedelic', Journal of Psychoactive Drugs, vol. 28 (3), pp. 267-290. https://www.ncbi.nlm.nih.gov/pubmed/8895112

Abstract:

This paper investigates the supposedly psychedelic Bufo toad and the allegedly psychedelic drug bufotenine, which is contained in the skin and glands of this toad. The bufo toad has held a place in human mythologies and medicines worldwide since archaic times. Used by ancient peoples for a variety of purposes, its most spectacular effects, according to lore, involve magical and shamanic or occult uses for casting spells and for divination. In the Middle Ages, the Bufo toad was celebrated as a panacea and persecuted as a powerful poison. More recently, in the 1960s the Bufo toad was resurrected as a countercultural icon, with people purportedly licking or smoking the secretions to get high. Bufotenine has been at the center of a scientific debate since its discovery in 1893. This paper examines the extensive literature surrounding the Bufo toad and bufotenine, and untangles many of the myths and the misinformation that continue to vex both science and popular reporting. Finally, to promote further investigation, a comprehensive bibliography is provided that charts the history of the Bufo toad and bufotenine.


#36
Poetry and Art / Onyx Flux
May 01, 2017, 02:41:55 AM
Onyx Flux

Silver fractal shards pour into my sight,
spiralled out and piping in - a sudden liquid light.
Yielding to an emptiness, a space at once replete,
with boundless black expanse, infinite and complete.

Unfolding diamond-laden vista, quartz and crystalline, 
each-in-all and all-in-each, endless myriad facets shine.
In charged electric ether-sphere, a brilliant lightening white,
brings from depths within, an arcane obsidian night.

Sound vibrates this space in time and into being creates,
a vastly liminal zone; a pure awareness state.
An omnipresent force propels, the surge to rise and grow,
with pulsing, phasing current in eternal ebb and flow.

A vibratory purge, a harmonising clean,
Orgasmic oscillation of frequency unseen. 
In somatic symmetry of tension-borne release,
this fluid state of flux, reflects an inner peace.

Translucent beads of potency in molten motion course,
through quicksilver rivulets to the heart of source.
As Spirit moves in everything, everywhere and everywhen,
Its purity of perfection arrives at home again.

This body, I, a vessel see - the breath of life is me,
In gratitude of energy and re-membering to be.
From alpha to omega flows, eternal animation's shape,
Always here, always now- essence of is-ness agape.

As onyx mindscape dissolution, finds the centre core,
of true, eternal, love divine in soulgasm evermore.
Open - open - ever open... to receive with bliss; serenity,
in stillness grace abounds, wholly-holy integrity.


#37
As a composite of impressions taken from (at the time of writing) a dozen or so experiences with vapourised synthetic 5-MeO-DMT, my testimonial takes the form of a poem in what I am drawn to as a more fluid way of articulating such ineffability.

Onyx Flux

Silver fractal shards pour into my sight,
spiralled out and piping in - a sudden liquid light.
Yielding to an emptiness, a space at once replete,
with boundless black expanse, infinite and complete.

Unfolding diamond-laden vista, quartz and crystalline, 
each-in-all and all-in-each, endless myriad facets shine.
In charged electric ether-sphere, a brilliant lightening white,
brings from depths within, an arcane obsidian night.

Sound vibrates this space in time and into being creates,
a vastly liminal zone; a pure awareness state.
An omnipresent force propels, the surge to rise and grow,
with pulsing, phasing current in eternal ebb and flow.

A vibratory purge, a harmonising clean,
Orgasmic oscillation of frequency unseen. 
In somatic symmetry of tension-borne release,
this fluid state of flux, reflects an inner peace.

Translucent beads of potency in molten motion course,
through quicksilver rivulets to the heart of source.
As Spirit moves in everything, everywhere and everywhen,
Its purity of perfection arrives at home again.

This body, I, a vessel see - the breath of life is me,
In gratitude of energy and re-membering to be.
From alpha to omega flows, eternal animation's shape,
Always here, always now- essence of is-ness agape.

As onyx mindscape dissolution, finds the centre core,
of true, eternal, love divine in soulgasm evermore.
Open - open - ever open... to receive with bliss; serenity,
in stillness grace abounds, wholly-holy integrity.






#40
Media/Resources / Articles
April 28, 2017, 05:20:05 AM
ARTICLES

A New Craze Hops into the Drug Culture Fads: The quest for new highs has led some seekers to a new low--toad smoking. It's weird, it's illegal, and experts warn that it's probably dangerous, too, by Leo W. Banks, Los Angeles Times, 1994, https://erowid.org/archive/sonoran_desert_toad/LATimes.htm

A Toad on the Moon: Or a Brief Speculation on Chinese Psychoactive Toad Venoms, by Frederick R. Dannaway, n.d., https://sites.google.com/site/delawareteasociety/a-toad-on-the-moon-or-a-brief-speculation-on-chinese-psychoactive-toad-venoms

At the Crossroads of Ibogaine and 5-MeO-DMT: An Interview with Dr. Martin Polanco, by Wesley Thoricatha, Psychedelic Times, 2015, http://psychedelictimes.com/iboga/at-the-crossroads-of-ibogaine-and-5-meo-dmt-interview-with-dr-martin-polanco/

Bufo Alvarius; A Personal Story, by Anon, n.d., https://erowid.org/archive/sonoran_desert_toad/mystory.htm

Bufo alvarius: The Psychedelic Toad of the Sonoran Desert, by Albert Most, 1983, https://erowid.org/archive/sonoran_desert_toad/almost.htm

Bufo Alvarius: The Psychedelic Toad That Contains 5-Meo-Dmt, by Jennifer Sodini, 2016, http://www.evolveandascend.com/2016/04/30/bufo-alvarius-psychedelic-toad-contains-5-meo-dmt/

The Essential Guide to 5-MeO-DMT,

Farmer Bob's Good Life, by Ward Parkway, n.d., [url=https://erowid.org/archive/sonoran_desert_toad/farmer.htm]https://erowid.org/archive/sonoran_desert_toad/farmer.htm


Give the Ego a Break, Cate Montana, 2016, https://www.catemontana.com/2016/08/give-the-ego-a-break/#more-1124

Goodbye Ecstasy, Hello 5-Meo-DMT: New Designer Drugs are Just a Click Away, by David McCandless, The Guardian, 2004, https://www.theguardian.com/society/2004/feb/16/drugsandalcohol.drugs

In Search of Hallucinogenic Toad, by Vice Staff, Vice, 2015, https://www.vice.com/en_au/article/the-toad-prophet-464

Instant Samadhi: the 5-MeO-DMT toad sacrament, by Guy Crittenden, 2017 http://guycrittenden.blogspot.com.au/2017/06/instant-samadhi-5-meo-dmt-toad-sacrament.html

Just Say No, by Brendan Joel Kelly, Phoenix New Times, 2004, http://www.phoenixnewtimes.com/music/just-say-no-6438439

Misuse and Legend in the "toad licking" Phenomenon, Thomas Lyttle,1993, https://erowid.org/archive/sonoran_desert_toad/LaLaw.htm#Lyttle

More details about my new book: The Toad and the Jaguar, by Ralph Metzner, 2014, https://ralphmetznerblog.com/tag/5-meo-dmt/

Personal Story: My 5-MeO-DMT Experience, by Jenn Bowers, Reset Me, 2015 http://reset.me/personal-story/personal-story-my-5-meo-dmt-experience/

Practicing Death, by Tom Pinkson, Spirituality & Health, 2010, http://spiritualityhealth.com/articles/practicing-death

Psychedelic Research with Ibogaine and 5-MeO-DMT: An Interview with Dr. Joseph Barsuglia, by Wesley Thoricatha, Psychedelic Times, 2016, http://psychedelictimes.com/iboga/psychedelic-research-with-ibogaine-and-5-meo-dmt-an-interview-with-dr-joseph-barsuglia/

Psychoactive Toads- Will licking toads make you high?, Trancentral, n.d., https://trancentral.tv/psychoactive-toads/

Reports of 5-MeO-DMT Experiences, by Anonymous, Serendipity, 2015, http://www.serendipity.li/dmt/1st5meo.html

Risks associated with combining Bufo Alvarius with ayahuasca, ICEERS, 2017 http://news.iceers.org/2017/05/alert-bufo-alvarius-and-ayahuasca/?utm_content=buffer8e88b&utm_medium=social&utm_source=facebook.com&utm_campaign=buffer

Schedules of Controlled Substances: Placement of 5-Methoxy-N,N-Dimethyltryptamine into Schedule I of the Controlled Substances Act, A Rule by the Drug Enforcement Administration on 2010, Federal Register The Daily Journal of the United States Government, https://www.federalregister.gov/documents/2010/12/20/2010-31854/schedules-of-controlled-substances-placement-of-5-methoxy-nn-dimethyltryptamine-into-schedule-i-of

Simona€s Bufo Alvarius (Colorado River Toad) Guide, Simonthesorcerer, n.d., https://simonsblogpark.com/legalhigh/simons-bufo-alvarius-colorado-river-toad-guide/

Smoking Toad, by Larry Gallagher, Esquire Magazine, 1994, http://www.larrygallagher.com/articles/toad.pdf

Smoking Toad Venom€, All About Heaven, n.d., http://www.allaboutheaven.org/overload/451/107/smoking-toad-venom

The God Molecule, by Gerardo Ruben Sandoval Isaac, Reality Sandwich, 2017, http://realitysandwich.com/320490/the-god-molecule/

The Georgetown Drug Lab Bust: More Promising Young Lives Ruined for No Good Reason, By Armin Rosen, The Hit & Run blog, 2010 https://reason.com/blog/2010/10/26/the-georgetown-drug-lab-bust-m

The Nuclear Option: A Personal Story of Treating Social Anxiety with 5-MeO-DMT Psychedelic Therapy, by Wesley Thoricatha, Psychedelic Times, 2016, http://psychedelictimes.com/5-meo-dmt/nuclear-option-personal-story-of-treating-social-anxiety-with-5-meo-dmt/

The Sex Life of the Psychedelic Toad, by Paul Rydeen, Crash Collusion, 1993, https://erowid.org/archive/sonoran_desert_toad/rydeen.htm

The Sonoran Desert Toad, Psychedelic and Toxic, Jonathan Duhamel, Arizona Daily Independent, 2014, https://arizonadailyindependent.com/2014/05/18/the-sonoran-desert-toad-psychedelic-and-toxic/

The Toad and the Jaguar - Profound 5-MeO-DMT Experiences, By Ralph Metzner, The Nexian , August 2014, http://the-nexian.me/home/experience-reports/119-the-toad-and-the-jaguar-profound-5-meo-dmt-experiences

Toad medicine: a 5-Meo-Dmt trip into cosmic consciousness, By Xavier October 2017, https://xabtc.wordpress.com/2017/10/17/toad-medicine-a-5-meo-dmt-trip-into-cosmic-consciousness/

The Toad Nut/Mother, by Christian Raetsch, n.d, https://erowid.org/archive/sonoran_desert_toad/toadNut.htm

Toad-Smoking Gains On Toad-Licking Among Drug Users --- Toxic, Hallucinogenic Venom, Squeezed, Dried and Puffed, Has Others Turned Off, by Bill Richards, Wall Street Journal, 1994, https://erowid.org/archive/sonoran_desert_toad/wallstreet.htm

Toad Suckers: Not Just an Urban Myth, By Chris Kilham, Fox News, 2011, http://www.foxnews.com/health/2011/07/06/toad-suckers-not-just-urban-myth.html

Toad Venom: Weird Trip or Cancer Cure?, by Abby Haglage, The Daily Beast, 2017, http://www.thedailybeast.com/articles/2016/04/30/toad-venom-weird-trip-or-cancer-cure.html

Tripping over Psychoactive Toads, Harriet Dickinson, The Naked Scientists, 2009, https://www.thenakedscientists.com/articles/features/tripping-over-psychoactive-toads

'Watch a Freelance Journalist Writhe Through a Powerful DMT Trip for Research, Clinton Nguyen, Motherboard, 2015, https://motherboard.vice.com/en_us/article/watch-a-freelance-journalist-writhe-through-a-powerful-dmt-trip-for-research

What Is the Difference between 5-MeO DMT and DMT? Choosing a DMT Therapy, by Roger R, Psychedelic Times, 2016, http://psychedelictimes.com/dmt/what-is-the-difference-between-5-meo-dmt-and-dmt-choosing-a-dmt-therapy/

Why Venom Now? 5meo DMT as Entheogen, by Christopher G Ewing, The Practical Tripper, 2016, https://thepracticaltripper.wordpress.com/2016/11/25/why-venom-now-5meo-dmt-new-tradition/

5-MeO-DMT, By Mike Cernovich, Danger & Play, 2012, https://www.dangerandplay.com/2012/06/19/5-meo-dmt/

5-MeO-DMT, The Spirit Molecule, Pineal Gland, Consciousness, and Atheism, By Mike Cernovich, 2014  https://www.dangerandplay.com/2014/08/04/5-meo-dmt-spirit-molecule/

5-MeO-DMT, broken down and described, Disregard Everything I say, 2014, http://disregardeverythingisay.com/post/98109177114/5-meo-dmt-broken-down-and-described